-+ 0.00%
-+ 0.00%
-+ 0.00%

Immix Biopharma Reports 75% Complete Response Rate in Phase 2 NXC-201 Trial for AL Amyloidosis

Reuters·12/08/2025 11:19:21

Please log in to view news